US › Healthcare

Evommune, Inc. (EVMN)

US · Healthcare · Biotechnology

$13.11+13.11%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-21.7M
Profit YoY
-48.9%
EPS
$-0.64
EPS estimate
$-0.85

EPS came in at -0.64 against a street estimate of -0.85 — a beat of 24.0%.

Key statistics

Market cap
$405.2M
Forward P/E
0.0
P/B
1.33
Book value
$8.46
EPS (TTM)
$-2.11
52-week high
$33.20
52-week low
$10.47
50-day MA
$17.26
200-day MA
$20.76

Analyst view

with an average price target of $31.14.

Shareholding

Insiders
3.18%
Institutions
114.82%

Largest institutional holders

FundStake
EQT Fund Management S.à r.l.13.69%
RA Capital Management, LLC9.70%
Pivotal bioVenture Partners Investment Advisor LLC5.35%
RTW INVESTMENTS, LLC4.17%
JPMorgan Chase & Co4.05%
MPM Oncology Impact Management LP4.04%
Nan Fung Group Holdings Ltd4.00%
Andera Partners3.86%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Evommune, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.